Lorukafusp

A4DAB159 | Phase-II
Ganglioside GD2
G1 / None
Lexigen Pharmaceuticals Apeiron Biologics Merck KGaA University of Wisconsin-Madison
Phase-II
Whole mAb Fusion
APN 301 APN301 APN-301 ch14.18-IL2 EMD 273063 EMD-273063 EMD273063
—
IMGT Thera-SAbDab YAbS
Avg A4D Score
-0.6777
Score Range
-0.72 to -0.65
Structures
7
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB159_4tuo_C_D 4tuo 95% -0.7042 6.5 4.0 -0.3851 -0.7425
A4DAB159_4tuk_H_L 4tuk 95% -0.6549 6.5 4.0 -0.3192 -0.6961
A4DAB159_4trp_H_L 4trp 95% -0.7177 6.5 4.0 -0.4224 -0.7509
A4DAB159_4tul_H_L 4tul 95% -0.6654 6.5 4.0 -0.2931 -0.7096
A4DAB159_4tuj_C_D 4tuj 95% -0.6498 6.5 4.0 N/A N/A
A4DAB159_4tuj_A_B 4tuj 95% -0.6712 6.5 4.0 -0.274 -0.7195
A4DAB159_4tuo_A_B 4tuo 95% -0.6805 6.5 4.0 -0.3565 -0.7201